BDNF and PDE4, but not the GRPR, regulate viability of human medulloblastoma cells

Anna Laura Schmidt1, Caroline Brunetto de Farias, Ana Lucia Abujamra

  • 1Cancer Research Laboratory, University Hospital Research Center (CPE-HCPA), Federal University of Rio Grande do Sul, Rua Sarmento Leite, 2350, 90035-003, Porto Alegre, RS, Brazil.

Insights

Brain-derived neurotrophic factor (BDNF) and phosphodiesterase-4 (PDE4) inhibitors impact medulloblastoma cell viability. Gastrin-releasing peptide receptor (GRPR) signaling does not influence these pediatric brain tumors.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Cellular signaling

Background:

  • Medulloblastoma is the most common pediatric brain tumor.
  • Neurotrophin and neuropeptide receptors are emerging molecular targets.
  • Understanding signaling pathways is crucial for developing new therapies.

Purpose of the Study:

  • To investigate the role of brain-derived neurotrophic factor (BDNF)/TrkB receptor and gastrin-releasing peptide receptor (GRPR) signaling in medulloblastoma cell viability.
  • To explore the effects of BDNF, GRPR agonists/antagonists, and a PDE4 inhibitor on medulloblastoma cell lines.

Main Methods:

  • Immunohistochemistry and reverse transcriptase polymerase chain reaction (RT-PCR) were used to confirm receptor and ligand expression.
  • Cell viability was assessed using the MTT assay.
  • Medulloblastoma cell lines (Daoy, D283, ONS76) were treated with BDNF, GRP, bombesin, RC-3095, and rolipram, alone or in combination.

Main Results:

  • BDNF significantly inhibited the viability of Daoy and D283 medulloblastoma cells, but not ONS76 cells.
  • GRPR agonists (GRP, bombesin) and antagonist (RC-3095) did not affect cell viability.
  • Rolipram (a PDE4 inhibitor) significantly reduced the viability of all three cell lines, with no modification by GRP cotreatment.

Conclusions:

  • BDNF/TrkB signaling pathway and phosphodiesterase-4 (PDE4) play a significant role in regulating medulloblastoma cell viability.
  • The gastrin-releasing peptide receptor (GRPR) pathway does not appear to influence the viability of these medulloblastoma cells.
  • These findings highlight potential therapeutic targets for medulloblastoma treatment.